Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor e2020 in rhesus monkeys

Psychopharmacology

Volumn 131, Issue 4, 1997, Pages 406-410

  Rupniak, Nadia M J ^a   Tye, Spencer J ^a   Field, Mark J ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

Acetylcholine; Alzheimcr's disease; Cognition; Palliative therapy; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; COGNITION; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; SPATIAL MEMORY; TASK PERFORMANCE; VISUAL MEMORY;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; ANIMALS; CHOLINESTERASE INHIBITORS; COGNITION; INDANS; MACACA MULATTA; MALE; MEMORY; PIPERIDINES;

EID: 0030803829     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050310     Document Type: Article

References (34)

1. Aigner TG, Mishkin M (1986) The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 45:81 87
2. Baratti CM, Huygens P, Mino J, Merlo A, Gardella J (1979) Memory facilitation with posttrial oxotremorine and physostigmine in mice. Psychopharmacology 64:85 88
3. Bartus RT, Dean RL (1988) Tetrahydroaminoacridine, 3,4-diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates. Neurobiol Aging 9:351 356
4. Bartus RT, Johnson HR (1979) Short-term memory in the rhesus monkey: disruption from the anticholinergic scopolamine. Pharmacol Biochem Behav 5:39 46
5. Bodick NC, DeLong AF, Bonate PL, Gillespie T, Henry DP, Satterwhite JH, Lucas RA, Heaton J, Carter GV, Farde L, Cutler NR, Sramek JJ, Seifert RD, Conrad JJ, Wardle TS (1994) Xanomeline, a specific M1 agonist: early clinical studies. In: Giacohini E, Becker R (eds) Alzheimer disease: therapeutic strategies. Birkhäuser, Boston, pp 234 238
6. Canal N, Franceschi M (1994) Eptastigmine (MF-201). A double-blind, placebo-controlled clinical trial in Alzheimer's disease patients. In: Giaconini E, Becker R (eds) Alzheimer disease: therapeutic strategies. Birkhäuser. Boston, pp 108 112
7. Christie JE, Shering A, Fergusson J, Glen AIM (1981) Physostigmine and arecoline: effects of intravenous injections in Alzheimer presenile dementia. Br J Psychiatry 138:46 50
8. Cox T, Tye N (1973) Effects of physostigmine on the acquisition of a position discrimination in rats. Neuropharmacology 12: 477 484
9. Davis KL, Mohs RC (1982) Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 139:1421 1425
10. Dawson GR, Iversen SD (1993) The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 57:143 153
11. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno JA (1992) A controlled trial of tacrine in Alzheimer's disease. JAMA 268:2523 2529
12. Fisher A, Hedman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Marcovitch I, Brandeis R, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD (1994) Selective signaling via novel muscarinic agonists: implications for Alzheimer's disease treatments and clinical update. In: Giacobini E, Becker R (eds) Alzheimer disease: therapeutic strategies Birkhäuser, Boston, pp 234-238
13. Fitten LJ, Perryman K, Tachiki K, Kling A (1988) Oral tacrine administration in middle-aged monkeys: effects on discrimination learning. Neurobiol Aging 9:221 224
14. Halliwell JV, Grove EA (1989) 9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones, Eur J Pharmacol 163:369 372
15. Hartvig P, Askmark H, Aquilonius SM (1990) Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 38:259 263
16. Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zenmishlany Z, Davis KL (1987) RS86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 22:1067 1078
17. Kumar V (1994) Introduction to cholinesterase inhibitors used in Alzheimer's disease therapy. In: Giacobini E, Becker R (eds) Alzheimer disease: therapeutic strategies. Birkhäuser, Boston, pp 99 102
18. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, Morishita N (1993) Pharmacokinetics of E2020. a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Therap Toxicol 31:223 229
19. Ogura H, Kosasa T, Araki S, Yamanishi Y, Yamatsu K (1988) Behavioural study of E-2020, a novel centrally acting acetylcholinesterase inhibitor. Soc Neurosci Abstr 14:60
20. Ohtani Y, Murasaki M, Ishii Y, Ishigooka J, Miura S (1990) Phase I study of FKS-508 single and multiple dose studies. Eur J Pharmacol 183:1038
21. Perry EK, Smith CJ, Court JA, Bonham JR, Rodway M, Atack JR (1988) Interaction of 9-amino-1,2,3,4- tetrahydroacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett 91:211 216
22. Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD (1989) Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 99:189 195
23. Rupniak NMJ, Field MJ, Samson NA, Steventon MJ, Iversen SD (1990)Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol Aging 11:609 613
24. Rupniak NMJ, Samson NA, Steventon MJ, Iversen SD (1991) Induction of cognitive impairment by scopolamine and noncholinergic agents in rhesus monkeys. Life Sci 48:893 899
25. Rupniak NMJ, Tye SJ, Brazell C, Heald A, Iversen SD, Pagella PG (1992a) Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates. J Neurol Sci 107:246 249
26. Rupniak NMJ, Tye SJ, Iversen SD (1992b) Comparison of the effects of selective and nonselective muscarinic agonists on cognition and thermoregulation in primates. J Neurol Sci 110: 222 227
27. Sarter M, Hagan J, Dudehenko P (1992) Behavioural screening for cognition enhancers: from indiscriminate to valid testing: part 1. Psychopharmacology 107:144-159
28. SCRIP (1996) Pfizer going for gold in Alzhemier's. SCRIP 2144:21
29. Siegfried K (1995) The efficacy of cholinergic drugs in patients with Alzheimer's disease focus on the aminoacridines. Hum Psychopharmacol 10:89 96
30. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K (1992) Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5, 6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett 2:871 876
31. Summers WK, Viesselman JO, Marsh GM, Candelora K (1981) Use of THA in treatment of Alzheimer-likc dementia: pilot study in twelve patients. Biol Psychiatry 16:145 153
32. Villalobos A, Butler TW, Chapin DS, Chen YL, DeMattos SB, Ives JL, Jones SB, Liston DR, Nagel AA, Nason DM, Nielsen JA, Ramirez AD, Shalaby IA, White WF (1995) 5,7-Dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[3, 2-f]-1,2-benzisoxazol-6-one: a potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety. J Med Chem 38:2802 2808
33. Watkins PB, Zimmerman HJ, Knapp MJ (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease, JAMA 271:992 998
34. Wettstein A, Spiegel R (1984) Clinical trials with the cholinergic drug RS86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 84:572 573